anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an artificially synthesized anticancer peptide and an acid-responsive nanoparticle precursor thereof. The nanoparticle is formed by connecting anticancer peptide and amphiphilic monomethyl polyethylene glycol-polypropylene glycol polymer through acid-responsive chemical bonds. Experiments prove that the anticancer peptide kills tumor cells through membrane breaking activity and has the advantages of excellent broad-spectrum anticancer activity and drug resistance. The nanoparticle is selectively sensitive to tumor subacid environment, can completely release anticancer peptide, and plays an active role in targeting tumor cell lines. And has the advantages of hemolysis resistance, high plasma stability, low in vivo system toxicity, systemic administration and the like. The nanoparticle has obvious inhibition effect on various tumor cells including triple negative breast cancer, and particularly has good clinical application potential on drug-resistant triple negative breast cancer.
In supine position, ultrasound probe will be placed on inguinal region, 2-3 cm below to the inguinal crease. Patients in this group will receive interfascial obturator nerve block under ultrasound guidance.
INTRODUCTION: Heterotopic ossification (HO), acquired or hereditary, is a diverse pathological condition defined by the production of extraskeletal bone in muscles, soft tissues, and connective tissues. Acquired HO is relatively prevalent and develops mostly in response to trauma, although its etiology is unknown. Genetic forms provide insight into the pathobiological mechanisms of this disorder. Fibrodysplasia ossificans progressiva (FOP) is a rare hereditary form of HO that can have a significant impact on affected individuals. FOP steadily weakens affected subjects and increases their risk of death.
AREAS COVERED: The U.S. Food and Drug Administration has recently approved the retinoid palovarotene as the first compound to treat heterotopic ossification in patients with FOP. This review provides a comprehensive overview of current and potential future pharmacotherapeutic options and their modes of action. The online databases PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched using the terms 'heterotopic ossification' and 'fibrodysplasia ossificans progressiva' or synonyms, with a special focus over the last 5 years of publications.
EXPERT OPINION: Approval of palovarotene, as the first retinoid indicated for reduction in the volume of new HO, may revolutionize the therapeutic landscape. However, long-term safety and efficacy data for palovarotene are currently lacking.
Decision-making in clinical medicine ideally is based upon evidence from randomized, placebo-controlled trials (RCTs) and subsequent systematic reviews and meta-analyses. However, for orphan diseases, the expectation of having one or multiple RCTs that inform clinical guidelines or justify specific treatments can be unrealistic and subsequent therapeutic nihilism can be detrimental to patients. This article discusses the benefits of therapeutic decision-making in the context of orphan diseases, focusing on primary sclerosing cholangitis (PSC) as an example of an orphan disease with poor clinical outcomes. PSC is a rare disorder characterized by inflammation and progressive fibrosis of the bile ducts. It carries a high risk of liver failure, malignancies, and debilitating symptoms that impair quality of life. Liver transplantation is currently the only life-prolonging intervention for PSC, but it is not a curative option. The article highlights the potential benefits of treating PSC patients with oral vancomycin (OV), which has shown significant clinical responses and improved quality of life in some cases. However, access to OV therapy is limited due to the lack of RCTs supporting its use. The standard requirement of having evidence from RCTs may result in withholding potentially life-altering and/or life-saving treatments for patients with orphan diseases. Conducting RCTs is challenging in these patient populations due to difficulties in recruiting the required patient cohorts and limited commercial returns. A standardized 'adaptive treatment strategy' is proposed to address this. This approach leverages the best available evidence for specific treatments, considers individual clinical responses, and adjusts treatment over time.
NEW MATERIAL:The compound of formula. USE:An antibacterial and antiviral agent. PREPARATION:The objective compound of formula can be produced by culturing Streptomyces alboniger IFO 12738 strain (a strain capable of producing the antibiotic substance pamamycin-607 of formula) in a liquid medium under aerobic condition at 25-35 deg.C for 120-192hr. The compound is an oily substance having the following physical and chemical properties. Optical rotation (measured immediately after the preparation of solution), [alpha]D=+22.8 deg. (c=0.26, methanol); solubility, easily soluble in acetone, methanol, ethanol, ethyl acetate and chloroform, hardly soluble in water; color reactions, detectable by iodine, vaniline sulfate or phosphomolybdic acid on TLC; etc.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to anaesthesiology, and can be used as an anaesthesia care in carotid endarterectomy in patients with critical ischemia of lower extremities and severe pain syndrome. That is ensured by preliminary puncture of the epidural cavity within the 11th thoracic to 3rd lumbar vertebras and introduction of amide local anaesthetics. Then, block of deep and durface cervical plexus is applied. ^ EFFECT: method allows to provide optimal conditions for adequate anaesthesia in a surgery in required amount in patients with multifocal atherosclerosis due to preliminary epidural anaesthesia levelling pain syndrome and related positional discomfort caused by base anaesthesia. ^ 1 ex
PURPOSE: An anti-obesity composition containing zingerone-4-O-beta-glucopyranoside is provided to ensure safe anti-obesity effect. CONSTITUTION: An anti-obesity composition contains zingerone-4-O-beta-glucopyranoside as an active ingredient. The active ingredient is isolated from Brassica rapa. A method for preparing zingerone-4-beta-glucopyranoside comprises: a step of extracting Brassica rapa. with methanol; a step of extracting the methanol extract with ethanolacetate/water and extracting a water layer with n-butanol/water; a step of decompressing each layer to prepare an ethanol acetate, n-butanol, and water fractions; a step of performing silicagel column chromatography of the n-butanol fraction to prepare 16 fractions(BRB-1 to BRB-16); a step of performing silica gel column chromatography of 6th fraction among 16 fractions to obtain 12 small fractions(BRB-6-1 to BRB-6-12); a step of performing silicagel column chromatography of 10th small fraction to obtain 7 small fractions(BRB-6-10-1 to BRB-6-10-7); and a step of purifying by octacetyl silicagel column chromatography. The composition is a food or pharmaceutical composition.
POETIC will test a patient-oriented, outpatient physiotherapy intervention tailored to each patient based on their symptoms, functional limitations, and goals. The intervention consists of eight one-on-one, supervised sessions delivered over 8 to 10 weeks, approximately one week apart. Each session will be approximately one hour long.
PROBLEM TO BE SOLVED: To reduce an initial facility investment in a home health management system and the burden on a system operating and maintenance staff. SOLUTION: A customer 5 registers a vital sign and clinical interview answers in a vital information database 22 from a home health management terminal 50. A medical institution 3 and a health service trader 4 generate comments by referring to the vital information database 22 through health management data reference viewers 30 and 40 and register them in an information providing database 23. When existent contents in a health-relative information database 21 are used as advice information, they are also registered. The customer 5 refers to the comments and advices in the information providing database 23 through the home health management terminal 50. A specific individual 6 refers to the health state of the parents, etc., at a remote place through a specific-individual's terminal 60. A health management database server 20 calculates the storage charge and bills it to the medical institution 3 and health service trader 4.
The invention discloses a medicine for treating leukemia, which is made from agrimony, rhizoma lmperatae, red jujube and water decoction, wherein, 100-140g of the agrimony, 40-70g of the rhizoma lmperatae and 90-110g of the red jujube are contained. The invention has the advantages of simple serving method, comfort feeling, low price and obvious efficacy. No radiotherapy and chemotherapy is required. The pains of the radiotherapy and chemotherapy on patients are avoided. The treatment course is short, the cure rate is high, and the total treatment course includes ten months. And the recurrence is uneasy after the cure.
BACKGROUND: Blount disease can occur at any time during the growth process, primarily with a bimodal distribution in children younger than 4 years old and adolescents. The disease process most commonly presents in Black adolescents, with disease severity positively correlated with obesity. Given the known associations among race, obesity, and socioeconomic status, we investigated the relationship between the degree of social deprivation and severity of lower extremity deformities among a community-based cohort with Blount disease.
METHODS: A retrospective review of hospital records and radiographs of patients with previously untreated Blount disease was conducted. Patients were classified as having early-onset or late-onset Blount disease based on whether the lower limb deformity was noted before or after the age of 4 years. The area deprivation index (ADI), a nationally validated measure that assesses socioeconomic deprivation by residential neighborhood, was calculated for each patient as a surrogate for socioeconomic status. Higher state (range: 1 to 10) or national (range: 1 to 100) ADI corresponds to increased social deprivation. Full-length standing radiographs from index clinic visits were evaluated by 2 reviewers to measure frontal plane deformity. The association of ADI with various demographic and radiographic parameters was then analyzed.
RESULTS: Of the 65 patients with Blount disease, 48 (74%) children were Black and 17 (26%) were non-black children. Nineteen children (32 limbs) had early-onset and 46 children (62 limbs) had late-onset disease. Black patients had significantly higher mean state (7.6 vs. 5.4, P =0.009) and national (55.1 vs. 37.4, P =0.002) ADI values than non-black patients. Patients with severe socioeconomic deprivation had significantly greater mechanical axis deviation (66 mm vs. 51 mm, P =0.008). After controlling demographic and socioeconomic factors, the results of multivariate linear regression showed that only increased body mass index (β=0.19, 95% CI: 0.12-0.26, P <.001) and state ADI (β=0.021, 95% CI: 0.01-0.53, P =.043) were independently associated with greater varus deformity.
CONCLUSIONS: Socioeconomic deprivation was strongly associated with increased severity of varus deformity in children with late-onset Blount disease. Our analysis suggests that obesity and socioeconomic factors are the most influential with regard to disease progression.
LEVEL OF EVIDENCE: Level III.
This clinical study is a phase 4, single-site, open-label pharmacokinetic (PK) study of IV artesunate in up to 100 Ugandan children 6 months-14 years of age who are diagnosed with severe malaria according to standardized World Health Organization (WHO) criteria (any P. falciparum parasitemia and the presence of danger signs). Participants will receive the standard of care IV artesunate for initial treatment of severe malaria per WHO guidelines: children weighing \<20 kg should receive 3.0 mg/kg/dose compared to children weighing =20 kg who should receive 2.4 mg/kg/dose, at times 0, 12, 24, 48 and 72 hours (WHO 2015). Parenteral treatment will be administered for a minimum of 24 hours (irrespective of the patient's ability to tolerate oral medication earlier), after which patients will be evaluated clinically and assessed for ability for oral intake of antimalarials. Children who are able to transition to oral antimalarial therapy will initiate a 3-day course of artemisinin-combination oral therapy per national guidelines. Biomarkers of physiologic dysfunction will be quantified at regular intervals, including serum lactate, serum glucose, total and direct bilirubin, bicarbonate levels, Blantyre Coma Score (BCS), creatinine and hemoglobin. These biomarkers will be considered both independently and together as a weighted score to relate to the PK of the active metabolite of IV artesunate, DHA and to efficacy markers that more accurately reflect clinical outcomes. We will also quantify P. falciparum parasitemia using standardized thick blood smear and relate this outcome to DHA dose and exposure for comparison with historical studies. Children 6 months to 14 years of age living in or near Tororo District, Uganda, who are diagnosed with severe malaria and who meet inclusion and exclusion criteria will be enrolled.
BACKGROUND: Bawei Chenxiang Wan (BCW) is among the most effective and widely used therapies for coronary heart disease and angina pectoris in Tibet. However, whether it confers protection through a right-ventricle (RV) myocardial metabolic mechanism is unknown.
METHODS: Male Sprague-Dawley rats were orally administrated with BCW, which was injected concurrently with a bolus of Sugen5416, and subjected to hypoxia exposure (SuHx; 5000 m altitude) for 4 weeks. Right ventricular hypertrophy (RVH) in high-altitude heart disease (HAHD) was assessed using Fulton's index (FI; ratio of RV to left ventricle + septum weights) and heart-weight-to-body-weight ratio (HW/BW). The effect of therapeutic administration of BCW on the RVH hemodynamics was assessed through catheterization (mean right ventricular pressure and mean pulmonary artery pressure (mRVP and mPAP, respectively)). Tissue samples were used to perform histological staining, and confirmatory analyses of mRNA and protein levels were conducted to detect alterations in the mechanisms of RVH in HAHD. The protective mechanism of BCW was further verified via cell culture.
RESULTS: BCW considerably reduced SuHx-associated RVH, as indicated by macro morphology, HW/BW ratio, FI, mPAP, mRVP, hypertrophy markers, heart function, pathological structure, and myocardial enzymes. Moreover, BCW can alleviate the disorder of glucose and fatty acid metabolism through upregulation of carnitine palmitoyltransferase1ɑ, citrate synthase, and acetyl-CoA and downregulation of glucose transport-4, phosphofructokinase, and pyruvate, which resulted in the reduced levels of free fatty acid and lactic acid and increased aerobic oxidation. This process may be mediated via the regulation of sirtuin 3 (SIRT3)-hypoxia-inducible factor 1α (HIF1α)-pyruvate dehydrogenase kinase (PDK)/pyruvate dehydrogenase (PDH) signaling pathway. Subsequently, the inhibition of SIRT3 expression by 3-TYP (a selective inhibitor of SIRT3) can reverse substantially the anti-RVH effect of BCW in HAHD, as indicated by hypertrophy marker and serum myocardial enzyme levels.
CONCLUSIONS: BCW prevented SuHx-induced RVH in HAHD via the SIRT3-HIF1ɑ-PDK/PDH signaling pathway to alleviate the disturbance in fatty acid and glucose metabolism. Therefore, BCW can be used as an alternative drug for the treatment of RVH in HAHD.
The invention belongs to the technical field of biology, and particularly relates to application of a polypeptide for targeted inhibition of BCL6 in preparation of an anti-leukemia drug. In particular to an application of a polypeptide for targeted inhibition of BCL6 in preparing anti-blood tumor drugs. The amino acid sequence table of the polypeptide is shown as SEQ ID No.1 and SEQ ID No. 2. The polypeptide can be specifically combined with TRIB so as to block TRIB/BCL 6 interaction and promote BCL6 and BCR-ABL protein degradation, so that the polypeptide is applied to preparation of medicines for treating and preventing leukemia (such as Ph+B-ALL) and lymphoma. The prepared medicine has the advantages of obvious curative effect, less toxic and side effect and safe use in treating tumor diseases.
The invention relates to a preparation technology and a production method of a novel yellow decoction integrated dosage form. The novel yellow decoction integrated dosage form consists of the following raw material active ingredients in parts by weight: 5 parts of astragalus and 5 parts of dried orange peel. The production process comprises ultrasonic speed fluid energy milling, alcohol-water extraction, ultrasonic wave smashing and extracting, water decoction concentration, ultrasonic speed spray drying, nanometer grinding, high-pressure homogenization, nanoparticle preparation and the like. In the invention, the advantages of multi-coordination, multi-targeting and the like represented in a nano-carrier coupling technique are utilized. After large-scale production is performed, the production cost can be reduced greatly, the product quality can be enhanced greatly, and the targeting property and controlled release property of a medicament can be enhanced. A yellow decoction can be administrated internally and externally, and can be taken at four time intervals according to midnight-noon ebb-flow and the qi-blood flow rule of a human body. The yellow decoction can be prepared into a film forming agent and a transdermal agent which are attached to different positions of a human body respectively according to midnight-noon ebb-flow and the qi-blood flow rule of the human body and can be directly absorbed through skin.
1. Oligosaccharides of formula (I): in which n is an integer from 0 to 25; R1, R3, R4 and R5, identical or different, are a hydrogen atom or a SO3M radical; R2 and R6, identical or different, are a hydrogen atom or a SO3M or COCH3 radical, and M is sodium, calcium, magnesium or potassium, oligosaccharides mixtures and their diastereoisomeres. 2. Oligosaccharides of formula I according to claim 1, in which R4 is a hydrogen atom, oligosaccharides mixture and their diastereoisomeres. 3. Oligosaccharides of formula I according to claim 1 or 2, in which n is an integer from 0 to 10, oligosaccharides mixture and their diastereoisomeres. 4. Oligosaccharides of formula I according to claim 1 or 2, in which n is an integer from 0 to 6, oligosaccharides mixture and their diastereoisomeres. 5. Oligosaccharides of formula I according to claim 1 or 2, in which n is an integer from 1 to 10, oligosaccharides mixture and their diastereoisomeres. 6. A method for preparing oligosaccharides of formula I according to claim 1, characterized in that alkali metals or quaternary ammonium hydroxyde is added for reacting with oligosaccharides of formula I according to claim 1: in which n is an integer from 0 to 25; R1, R3, R4 and R5, identical or different, are a hydrogen atom or a SO3M radical; R2 and R6, identical or different, are a hydrogen atom or a SO3M or COCH3 radical, and M is sodium, calcium, magnesium or potassium, and isolate oligosaccharides mixtures and their diastereoisomeres. 7. The method according to claim 6, characterized in that the reaction is carried out in aqueous medium at 40 to 80 degree C and pH from 10 to 13. 8. The method according to one of claims 6 or 7, characterized in that 1-5% aqueous solution of alkali metals or quaternary ammonium hydroxyde is used. 9. The method according to one of claims 6 to 8, characterized in that the reaction is carried out at 60 to 70 degree C. 10. The method according to one of claims 6 to 9, characterized in that the pH of the reaction medium is from 11 to 12,5. 11. The method according to claims 6 to 10, characterized in that the alkali metals or quaternary ammonium hydroxyde is sodium, potassium, lithium, cesium and tetrabutylammonium hydroxyde. 12. A pharmaceutical compositions containing at least one oligosaccharide according to claim 1 as an active principle. 13. A pharmaceutical compositions containing at least one oligosaccharide according to one of claims 1-5 as an active principle. 14. Use oligosaccharides of formula (I) according to one of claims 1-5 for preparing a medicament suitable for preventing or treating diseases associated with inflammatory process, at which nitrous oxide (NO) is produced. 15. Use oligosaccharides of formula (I) according to claims 1-14 for preparing a medicament suitable for preventing or treating cerebral, cardiac, or peripheral vascular ischemias, osteoarthritis, traumas of the central nervous system, cranium, spinal and or cranium-spinal traumas, disseminated sclerosis, neuropathic pains and peripheral neuropathies, motor neuron diseases, lateral amyotrophic sclerosis, neuro-AIDS, Alzheimer's disease, Parkinson's disease, Huntington's chorea.
Participants assigned to the waitlist group complete a 2wk, 1mo, 2mo and 3mo survey over the 91-day study period. After the 91-days they receive access to the 91-day Self-Talk Journal for their own personal use.
CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
chronic obstructive pulmonary disease is a chronic inflammatory lung disease that cause obstructed airflow from the lungs. Symptoms include Breathing difficulty. cough, mucus production and wheezing. Its typically caused by long term exposure to irritating gasses or particulate matter, most often from cigarette smoker.

Emphysema and chronic bronchitis are two most common condition that contribute to chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease is progressive disease that gets over a time. Clinical trials will be Conducted in Gulab Devi chest hospital in Lahore. Through the convenient sampling Technique. Which will be allocated through the random sampling two groups are involved group A and group B. In group A check the effect of Senobi techniques (stretch the body) and in group B check the effect of Buteyko technique. (Inhale the through the nose while mouth is closed) by using 6 mint walk test, Borg scale and quality of life questionnaire. Apply the technique to check the effectiveness of dyspnea and quality of life of patient The Buteyko technique offers a complementary method of reliving respiratory symptoms based on the voluntary control of breathing as well as considering the effect of environmental and dietary trigger. Data will be collected by the questionnaire and analyzed by using statistical package for the social science SPSS software version 21. The Buteyko method made its way to Australia to Europe and the unite states in 1990, it become best for the asthma and chronic obstructive pulmonary disease patient. The Senobi stretch exercise of the respiratory muscle improve the chest expansion and also improve the chest wall mobility in chronic obstructive pulmonary disease patient. Senobi breathing exercise was found to be effective for depression and it regulate the sympathetic nerve activity.
Placebo drug indistiguishable from pravastatin 40mg tablet, by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.